MI-EATON-VEHICLE-GROUP
10.8.2021 17:01:13 CEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has developed a series of 48-volt technologies to assist its global on- and off-highway commercial vehicle customers transitioning from traditional 12- and 24-volt vehicle systems to systems that include 48-volt architecture. These 48-volt systems can power new, advanced energy-consuming components and can help reduce emissions and improve fuel economy and performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005722/en/
“This development comes as global vehicle manufacturers are making decisions to adopt new technologies to meet emissions regulations,” said Ben Karrer, manager, Technology Development, Eaton’s Vehicle Group. “Of the options available, 48-volt architectures are becoming more popular because they can decrease both CO2 and NOx simultaneously, which helps both our customers and the environment.”
Most vehicles have traditionally operated with a 12-volt system, but with tightening fuel economy regulations and new, advanced power-consuming components being added, increasing power needs are driving the move toward 48-volt systems.
Reduce mechanical loads and CO2 by powering systems with 48-volt architecture
Many vehicle systems today are powered directly from mechanical power generated by the engine, which runs 12-volt systems such as air conditioning and pumps. Eaton is developing 48-volt systems that include motor generators and inverters that generate 48-volt DC power for the vehicle. Eaton also produces 48-volt DC/DC converters that step power down from 48-volt vehicle architectures to power 12- and 24-volt systems.
48-volt system can heat aftertreatment catalyst to reduce NOx emissions
Collectively, new emissions regulations will reduce tailpipe NOx limits by up to 90%, accelerating the need for global engine manufacturers to employ additional emissions reduction strategies.
Eaton’s Vehicle Group is also developing power electronics for 48-volt electric catalyst heating, which provides heat directly to the vehicle’s aftertreatment system. This active heating helps catalyst components reach efficient operating temperatures faster upon engine start and maintain those temperatures during low load operation. This will be an essential strategy for reducing emissions to the levels required by future regulations.
“Forty-eight-volt power will also be used to power systems such as HVAC and the engine cooling fan, which are traditionally run by the engine,” said Karrer. “Today’s systems are not intelligent—you can’t control when they’re on or off or adjust the levels. Converting those components to electric alternatives allows you to intelligently control them and eliminate mechanical loads.”
Electrified cooling offers multiple environmental, efficiency improvements
An electrical engine cooling fan and electric air conditioning compressor are also under development. Electrifying the cooling fan provides additional benefits, as it could be reduced in size and strategically placed within the engine bay, allowing for aerodynamic design flexibility to increase fuel economy and reduce emissions.
Supercapacitors, lead-acid batteries for 48-volt system power storage
Eaton’s Vehicle Group is developing a wide range of 48-volt energy storage solutions, including lead-acid batteries and supercapacitors.
“We’re integrating various energy storage technologies into a larger storage pack including controls, fusing, and contactors,” said Karrer. “Eaton’s Electrical Components Group is our partner for supercapacitors, and we will be working with most commercial vehicle battery manufacturers for lead-acid batteries.”
Lead-acid batteries are inexpensive compared to lithium-ion packs and offer a safe and more efficient solution, with a longer lifespan when compared to existing lead-acid battery applications.
Supercapacitors are able to quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don’t retain high levels of energy in comparison or require a liquid cooling system, and they have a longer cycle life.
This suite of technologies is an example of how Eaton is working to achieve its 2030 Sustainability Targets , which include reducing the carbon emissions from our operations by half and lowering product and supply chain emissions. Learn more about our commitment to improving the quality of life and the environment.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
